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cense.Abstract Background and objectives: It has become evident that ﬁbromodulin and other members
of the proteoglycan family are not only involved in collagen ﬁbrillogenesis and cell adhesion but they
also contribute to modulation of cytokine activity, suppression of tumor growth, and prevention of
apoptosis. Fibromodulin has been characterized as one of the tumor associated antigens (TAA) in B
cell chronic lymphocytic leukemia (B-CLL) with the potential to elicit speciﬁc antitumor response
and it is considered as good candidate for immunotherapy.
Aim of work: to study the expression of ﬁbromodulin at the gene level of B-cell chronic lymphocytic
leukemia patients, in comparison to normal controls and to asses its role in the pathophysiology of
CLL.
Patients and methods: Fibromodulin gene expression was tested by one step reverse transcription-
polymerase chain reaction (RT-PCR) in peripheral blood mononuclear cells of 30 patients with
B-CLL as well as in 20 age and sex matched healthy volunteers.
Results: In this study, ﬁbromodulin gene was expressed in 46.7% of patients with B-CLL which was
signiﬁcantly different from the control age and sex matched healthy volunteers in which none of them
showed peripheral blood mononuclear cells positivity for ﬁbromodulin gene expression (0%)
(p-value=0.006).We also found signiﬁcant associations between higher ﬁbomodulin gene expression
and some risk factors in the studied CLL cases such as hepatomegaly, lower haemoglobin level, lower5004325.
.com (R. Mohamed Samy).
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12 D.A. El-hamid Hassan et al.RBCs count, lower platelet count and borderline signiﬁcant associations with other risk factors as
lymphadenopathy and splenomegaly.
Conclusion: Our results suggest that ﬁbromodulin can be used as a target for therapeutic interven-
tion and it may play a role in the pathophysiology of CLL.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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Allogeneic hematopoietic cell transplantation (HCT) is the only
potentially curative therapy for B-CLL, but due to the high
treatment-related mortality and advanced age of most patients,
the procedure is not applicable for the majority of B-CLL pa-
tients. B-CLL is a very attractive disease to be targeted by
immunotherapy due to its rather low progression and due to
the availability of cancer cells in the peripheral blood [1]. Immu-
notherapy promises to mitigate the complications of chemo-
therapy and potentially provide for curative treatment [2].
Vaccine approaches in this disease have largely focused on
inducing effective autologous immune mediated responses
against tumor antigens expressed on the CLL cells. It has also
been demonstrated that CLL cells are very effective targets of
the allogenic graft versus leukemia effect and there is consider-
able interest in developing strategies to exploit this phenome-
non, particulary following reduced intensity conditioning
allogeneic stem cell transplantation. If successful, using the im-
mune system to treat this otherwise incurable disease could pro-
vide an approach that is distinct from traditional chemotherapy
[3]. Recently, it has been described that vaccination with allo-
genic dendritic cells (DCs) pulsed with tumor cell lysate gener-
ated speciﬁc cytotoxic CD8+ T cell response against the
leukemia-associated antigens, such as ﬁbromodulin, which have
been detected in patients with B-CLL [4]. For the development
of T-cell based therapies, the deﬁnition of immunogenic tumor-
associated antigens (TAAs), which are expressed in malignant
cells from leukemia/cancer patients but not in tissues of healthy
volunteers, constitutes a cornerstone. RHAMM/CD168, ﬁbro-
modulin, survivin and the oncofetal antigen immature laminin-
receptor protein (OFAiLRP) have been characterized as TAAs
in B-CLL with the potential to elicit speciﬁc anti-tumor re-
sponse and considered as good candidate targets for immune
therapy [5]. Fibromodulin mRNA has been detected in a variety
of clinical malignancies, such as lung, breast, and prostate car-
cinomas. Fibromodulin has a role in regulating stroma ECM
structure and ﬂuid balance in carcinoma [6]. Through study of
the global gene expression proﬁle of B-cell chronic lymphocytic
leukemia (B-CLL) cells, ﬁbromodulin was found to be one of
the most overexpressed genes [7].
Our work aimed at studying the expression of ﬁbromodulin
gene in CLL patients as a target for immunotherapy.Patients, materials, and methods
The present study was conducted on 30 newly diagnosed
chronic lymphocytic leukemia patients during the period from
March 2009 to February 2010 among cases referred to the
Medical Oncology Department of Kasr El-Aini hospitals,
Cairo University after taking informed consents. Criteria for
diagnosis of CLL according to the National Cancer Insti-tute-Working group (NCI-WG) were applied. The diagnosis
was based on coexpression of (CD5+/CD19+/CD23+/light
chain restriction/weak expression of sIg) by immunophenotyp-
ing and on the presence of more than 5.0 · 109/L lymphocytes
in peripheral blood. They were 23 male (76.7%) and 7 females
(23.3%) with male to female ratio of 3.3:1. Their age ranged
between 39 and 79 years with a median 60.5 years. Twenty
apparently healthy age and sex matched adults were enrolled
as a control group after taking informed consents. They were
14 male (70%) and 6 females (30%) with male to female ratio
of 2.3:1. Their age ranged between 40 and 65 years with a med-
ian 55.5 years.
Five milliliters of venous blood were taken from each pa-
tient and control under complete aseptic precautions on
1.5 mg/ml ethylene diamine tetra-acetic acid (EDTA) and were
divided for complete blood picture and the study of ﬁbromod-
ulin gene expression by RT-PCR.
Total RNA was extracted from tumor cells and normal
PBMCs using QIAamp RNA extraction kit (QIAGEN, Cata-
log number: 52304) according to the manufacturer’s instruc-
tions (according to QIAamp RNA blood Mini Handbook,
2006). Fibromodulin detection by one step RT-PCR was per-
formed using the QIAGEN OneStep RT-PCR Kit. (QIAGEN,
Catalog number: 210210, Germany). First-strand cDNA was
synthesized using 8 lg total RNA in 50 lL reaction mixture
consisting of 24 lL RNase-free water, 10 lL QIAGEN One-
Step RT-PCR Buffer (5· concentrated, containing TrisÆCl,
KCl, (NH4)2SO4, 12.5 mM MgCl2, dithiothreitol DTT;
12.5 mM MgCl2, pH 8.7), 2 lL dNTP Mix (containing
10 mM of each dNTP), 2 lL QIAGEN OneStep RT-PCR En-
zyme Mix (Omniscript and Sensiscript Reverse Transcriptases
and HotStarTaq DNA Polymerase) and 2 lL of each forward
and reverse primers (5 lM each). The mixture was incubated in
thermal cycler (PERKIN ELMER PCR system 9600, USA) at
42 C for 45 min for reverse transcription and initial activation
step was performed for 15 min at 95 C. PCR ampliﬁcation
was performed using ﬁbromodulin-speciﬁc primers 50-
ACCGTCCCCGATAGCTACTT-30 as sense and 50-CAT-
CCTGGACCTTCCAGCAAA-30 as antisense [7]. PCR was
performed for 35 cycles at 92 C for 30 s (denaturation),
60 C for 30 s (annealing), and 72 C for 30 s (extension).
The ampliﬁed products were separated on 2% agarose gel
electrophoresis, stained with ethidium bromide and visualized
under UV light. The results were documented using a Polaroid
camera with a red orange ﬁlter. The sample was considered
positive when a clear, sharp, distinct band was observed at
the speciﬁc molecular weight 480 bp. b-Globin gene was used
as a control for the quality of cDNA with sense primer
50-CAACTTCATCCACGTTCACC-30 and reverse primer
50-GAAGAGCCAAGGACAGGTTAC-30. PCR was per-
formed for 35 cycles at 94 C for 60 s, 58 C for 60 s and
72 C for 60 s. The ampliﬁed products were separated on 2%
agarose gel electrophoresis and positive sample showed a clear,
Figure 1 Fibromodulin gene expression by RT-PCR of some
CLL patients. Lane 1 represents the molecular weight (MW)
marker. It shows bands at MWs: 100, 200, 300, 400, 500, 600, 700,
800, 900, and 1000 bp. Lanes 2, 3, 5, 6, 8 and 10 are positive for
ﬁbromodulin gene expression (band at 480 bp) in CLL patients.
Lanes 4, 7 and 9 are negative for ﬁbromodulin gene expression in
CLL patients.
Table 1 Comparison between CLL patients and control
group regarding age, sex and gene expression.
CLL patients
(No. = 30)
Controls
(No. = 20)
p-Value
Age (years)
Median (range) 60.5 (39–79) 55.5 (40–65) 0.709
Sex
Male 23 (76.7%) 14 (70.0%) 0.847
Female 7 (23.3%) 6 (30.0%)
Male to female ratio 3.3:1 2.3:1
Fibromodulin expression 46.7% 0.0% 0.006
Table 2 Clinical characteristics of 30 CLL patients at the time
of testing.
Parameter No. (%)
Lymphadenopathy 20 (66.7%)
Splenomegaly 20 (66.7%)
Hepatomegaly 13 (43.3%)
Anemia* 22 (73.3%)
Thrombocytopenia* 14 (46.7%)
Rai staging
Stage 0 4 (13.3%)
Stage I 0
Stage II 4 (13.3%)
Stage III 8 (26.6%)
Stage IV 14 (46.6%)
Scoring system [11]
Score 4 17 (56.7%)
Score 5 13 (43.3%)
The duration since diagnosis ranged between 0 and 12 months with
a mean value 5.26 ± 4.03.
* Anemia (Hb < 11 g/dL), thrombocytopenia (Plts < 100 · 109/L)
according to the Rai staging system [12].
Fibromodulin gene expression in CLL 13sharp band at 268 bp. The size of the ampliﬁed product was
read with the use of a DNA ladder of different molecular
weights (fermentas, NoLimits 100 bp DNA Fragment,
Catalog number: SM1441).
Statistical methods:
Data were statistically described in terms of range, mean, stan-
dard deviation (SD), median, frequencies (number of cases)
and percentages when appropriate. Comparison of quantita-
tive variables between the study groups was done using the
Mann–Whitney test for independent samples. For comparing
categorical data, the Chi square (x) test was performed. Exact
test was used instead when more than 20% of cells have the ex-
pected frequency is less than 5. A probability value (p-value)
less than 0.05 was considered statistically signiﬁcant. All
statistical calculations were done using computer programs
Microsoft Exel 2003 (Microsoft Corporation, NY, USA) and
SPSS (Statistical package for the Social Science; SPSS Inc.,
Chicago, IL, USA) version 15 for Microsoft Windows.
Table 3 Fibromodulin gene expression in relation to clinical
data of 30 CLL patients.
Fibromodulin expression p-Value
Positive (n= 14) Negative (n= 16)
Lymphadenopathy
Yes (No. = 20) 12/20 (60%) 8/20 (40%) 0.058
No (No. = 10) 2/10 (20%) 8/10 (80%)
Splenomegaly
Yes (No. = 20) 12/20 (60%) 8/20 (40%) 0.058
No (No. = 10) 2/10 (20%) 8/10 (80%)
Hepatomegaly
Yes (No. = 13) 9/13 (69.2%) 4/13 (30.8%) 0.030*
No (No. = 17) 5/17 (29.4%) 12/17 (70.6%)
* Signiﬁcant difference (p 6 0.05).Results
The present study was conducted on 30 chronic lymphocytic
leukemia patients. They were 23 male (76.7%) and 7 females
(23.3%) with male to female ratio of 3.3:1. Their age ranged be-
tween 39 and 79 years with a median of 60.5 years. There were
twenty apparently healthy age and sex matched adults as a con-
trol group. They were 14 males (70%) and 6 females (30%) with
male to female ratio of 2.3:1. Their age ranged from 40 to
65 years with a median 55.5 years. Results of ﬁbromodulin gene
expression: CLL patients and controls were subjected to one
step RT-PCR, 14/30 were positive (46.7%) for ﬁbromodulin
gene expression, while all of the control group were negative
20/20 (100%) (p-value = 0.006). (Fig. 1 and Table 1).The main clinical characteristics of the CLL patients
included in our study (risk factors according to the modiﬁed
Rai staging system) are summarized in Table 2.
Relationships between ﬁbromodulin gene expression and
different risk factors were studied. Patients with lymphadenop-
athy or splenomegaly had higher percentage of positive ﬁbro-
modulin gene expression (60%) compared with those without
Table 4 Fibromodulin gene expression in relation to hema-
tological data of 30 CLL patients.
Parameter Positive
(n= 14)
Negative
(n= 16)
p-Value
Hb g/dl 8.66 ± 1.89* 10.44 ± 2.13 0.020
(5.5–12.5) (5.4–13.7)
RBC · 1012/L 3.26 ± 0.80 3.89 ± 0.80 0.042
(2.12–4.71) (2.01–4.82)
Plts · 109/L 97.93 ± 72.87 96.50 ± 110.84 0.011
(25–274) (38–456)
TLC · 109/L 60.23 ± 63.75 67.25 ± 47.75 0.480
(12.0–256.0) (10.4–170.0)
Lymphocytic
count · 109/L
80.76 ± 14.37 83.19 ± 9.88 0.707
(50.0–97.0) (60.0–98.0)
* Mean ± SD, SD: standard deviation (range).
14 D.A. El-hamid Hassan et al.lymphadenopathy or without splenomegaly (20%) with
borderline signiﬁcance (p-value = 0.058). Patients with hepa-
tomegaly had signiﬁcantly higher percentage of ﬁbromodulin
gene expression (69.2%) compared with those without hepato-
megaly (29.4%) (p-value = 0.030), (Table 3).
As regarding laboratory data, signiﬁcant relations were
detected between ﬁbromodulin gene expression and lower
hemoglobin level (<11 g/dl) (p-value = 0.020), lower RBCs
count (p-value = 0.042) and lower platelet count (<100 ·
109/L) (p-value = 0.011) but insigniﬁcant relations were
detected with TLC count (p-value = 0.480) and lymphocytic
count (p-value = 0.707), (Table 4).Discussion
There are several considerations that make antileukemic vacci-
nation a potential therapeutic approach for CLL. Firstly, the
majority of CLL patients has advanced age and need treatment
options with low toxicity. Secondly, most of the patients have
a long period of indolent disease which does not need aggres-
sive intervention. Thirdly, the utility of an antileukemic
immune response in controlling the disease is emphasized by
the graft-versus-leukemia effect associated with allogeneic
stem cell transplants and donor lymphocyte infusions [8].
CLL should be an ideal target for immune-mediated
responses. CLL arises from B cells that can act as antigen-pre-
senting cells (APCs), express unique tumor antigens, and has
been shown to be a target for the allogeneic T cells which medi-
ate a graft-versus-leukemia effect [9]. B-CLL cells may express
or overexpress a number of tumor-associated antigens (TAAs)
that can be the target of speciﬁc cytotoxic T-lymphocyte (CTL)
responses like ﬁbromodulin [4].
Our study aimed at studying ﬁbromodulin gene expression in
CLL patients as a good target for immunotherapy. Analysis of
results of one step RT-PCR for detection of ﬁbromodulin gene
among the studied groups revealed the following results: ﬁbro-
modulin gene was expressed in 14 of 30 CLL patients (46.7%), it
was not expressed in all the control groups 0/20 (0%).
Our results are comparable to the study of Giannopoulos
et al., in 2006 who found several expression patterns of TAAs
in B-CLL patients versus healthy volunteers (HVs). B-CLL pa-tients and healthy Volunteers (HVs) were examined by conven-
tional and quantitative RT-PCR for mRNA of ﬁbromodulin
and other tumor associated antigens, more than half of the
examined B-CLL patients showed positive mRNA expression
for ﬁbromodulin (63%) but not in HV [4]. While, in another
study, Mikaelsson et al. [5] reported that ﬁbromodulin expres-
sion was noticed at the gene level, using both RT-PCR and
Real-time quantitative PCR, in all patients with B-CLL
(100%) and in most patients with mantle cell lymphoma
(MCL). No mutations in the ﬁbromodulin gene were detected.
Fibromodulin was also detected at the protein level in the cyto-
plasm of the B-CLL cells and in the supernatant after in vitro
cultivation, but not at the cell surface. They also found that
ﬁbromodulin was not expressed in patients with T-cell chronic
lymphocytic leukemia (T-CLL), B-cell prolymphocytic leuke-
mia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), hairy
cell leukemia, follicular lymphoma, lymphoplasmacytic lym-
phoma, multiple myeloma, acute lymphoblastic leukemia
(ALL), acute myelogenous leukemia (AML), or chronic
myelogenous leukemia (CML) or in 36 hematologic cell lines.
Normal blood mononuclear cells (T and B lymphocytes,
monocytes), tonsil B cells, and granulocytes did not express
ﬁbromodulin [5]. They concluded that understanding the
biologic functions of ﬁbromodulin in B-CLL/MCL is critical
because this unique molecule may be used as a target for ther-
apeutic intervention [2]. This is also in agreement with Mayr et
al. [10], who reported that ﬁbromodulin is highly overexpres-
sed in CLL cells (100%) compared with normal B lymphocytes
by gene expression proﬁling. In their study, over expression of
ﬁbromodulin using real time RT-PCR was observed for all
leukemic samples at the mRNA level, while expression of
ﬁbromodulin was not detected in chronic myeloid leukemia
(CML) patients, acute lymphoblastic leukemia (ALL) patients
and in peripheral blood mononuclear cells (PBMCs) of healthy
donors tested. The lower frequency of ﬁbromodulin gene
expression in our studied cases (46.7%) in comparison to the
other mentioned studies which were 63% by Giannopoulos
et al. [4], 100% by Mikaelsson et al. [5] and 100% by Mayr
et al. [10] might be attributed to more sensitive techniques used
by them.
The modiﬁed Rai staging system classiﬁes CLL patients
into low-risk patients with only lymphocytosis in the PB and
BM (stage 0), intermediate-risk patients with lymphocytosis
and lymphadenopathy (stage I) and/or hepato-splenomegaly
(stage II) and high-risk patients with lymphocytosis together
with anemia (Hb < 11 g/dL) (stage III) and/or thrombocyto-
penia (Plts < 100 · 109/L) (stage IV). In an attempt to corre-
late ﬁbromodulin gene expression with risk factors in CLL
according to the Rai staging system which is the most
commonly used in CLL; our data revealed that ﬁbromodulin
gene expression was signiﬁcantly higher among patients with
hepatomegaly (p-value = 0.030) and borderline signiﬁcantly
higher among patients with lymphadenopathy (p-value =
0.058) and splenomegaly (p-value = 0.058). Signiﬁcant rela-
tions were also detected between ﬁbromodulin gene expression
and lower hemoglobin level (p-value = 0.020), lower RBCs
count (p-value = 0.042) and lower platelet count (p-value =
0.011). There were insigniﬁcant relations regarding TLC count
(p-value = 0.480) and lymphocytic count (p-value = 0.707).
These results indicate that expression of ﬁbromodulin gene
may have a role in the pathogenesis of CLL being related to
higher risk factors, but more prospective studies on higher
Fibromodulin gene expression in CLL 15number of cases may be needed to support its possible role in
the pathophysiology of CLL. Follow up of patients is highly
recommended to discuss the prognostic role of the ﬁbromodu-
lin gene.
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